FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 289 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Ivosidenib with Chemotherapy New Option for Some People with AML May 13, 2022 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz November 12, 2019 iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... November 14, 2024 Load more HOT NEWS Learning From Being Lost ΠΩΣ ΠΡΟΚΑΛΕΙΤΑΙ 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... ESMO AI & Digital Oncology Congress 2025 Closed in Berlin under...
